Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies

Clinical Pharmacokinetics

Volumn 53, Issue 5, 2014, Pages 479-488

  Salem, Ahmed Hamed ^a,b   Giranda, Vincent L ^a   Mostafa, Nael M ^a  

^a ABBVIE INC   (United States)

^b African Union Organization St Abbassia   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLACEBO; TEMOZOLOMIDE; VELIPARIB; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; ARTICLE; BODY SIZE; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CREATININE CLEARANCE; DEMOGRAPHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; LEAN BODY WEIGHT; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NON HEMATOLOGIC MALIGNANCY; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UTERINE TUBE TUMOR; WHOLE BRAIN RADIATION THERAPY; AGED; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; YOUNG ADULT;

EID: 84900849411     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0130-1     Document Type: Article

References (32)

1. Chiarugi A. Poly (ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci. 2002;23(3):122.
2. Virág L, Szabó C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
3. Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem/FEBS. 1980;104(1):279.
4. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol. 1991;37(4):223-7.
5. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16(3):338-44.
6. Hirai K, Ueda K, Hayaishi O. Aberration of poly (adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983;43(7):3441-6.
7. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277-90.
8. Penning TD, Zhu G-D, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2- yl]-1 H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2008;52(2):514-23.
9. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-37.
10. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726-34.
11. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011;71(17):5626-34.
12. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705-11.
13. Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos. 2011;39(7):1161-9.
14. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010;65(3):419-25.
15. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57.
16. Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM user's guide. Ellicott City: Icon Development Solutions; 1989-2009.
17. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51-64.
18. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000;39(3):215-31.
19. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43(15):1167-78.
20. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
22. Mosteller R. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
23. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-51.
25. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metabol Pharmacokinet. 2009;24(1):25-36.
26. Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115-22.
27. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67(1):93-101.
28. Morgan D, Bray K. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet. 1994;26(4):292.
29. Roche A, Heymsfield S, Lohman T, editors. Human body composition. Champaign (IL): Human Kinetics Press; 1996.
30. Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, et al. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci. 2013;102(12):4426-32.
31. Mehta MP, Curran WJ, Wang D, Wang F, Kleinberg L, Brade A, et al. Phase 1 safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (PTS) with brain metastases. J Thorac Oncol. 2012;84(3S):S269.
32. Middleton M, Friedlander P, Hamid O, Daud A, Plummer R, Schuster R, et al. Efficacy of veliparib (ABT-888) plus temozolomide versus temozolomide alone: a randomized, double-blind, placebo-controlled trial in patients with metastatic melanoma. Eur J Cancer. 2011;47:8.